BioSpace News Archive

Enrollment to cease immediately; topline data anticipated in H1 2021

ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced that Mr. Brendan Brennan, CFO of ICON plc

Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirine (Cami).

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial results for the quarter ended September 30, 2020 and provided a corporate update.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, and George Mason University’s (Mason’s) National Center for Biodefense and Infectious Diseases (NCBID), today jointly announce completion of extensive laboratory testing supporting anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate, which is being developed as a potential COVID-19 treatment.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA).

Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to people with acromegaly and the patient advocacy groups in their ongoing efforts to increase awareness of acromegaly and support the unique needs of people living with acromegaly.

Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.

Akerna Corp. (Nasdaq: KERN), (“Akerna” or the “Company”), a leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), today announced it has closed a public offering of 5,000,000 shares of its common stock at a public offering price of $2.40 per share.

Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $119 million contract from the United States government to expand its production capacity for COVID-19 molecular tests.